The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.
Also called NCT05042973
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 165 participants
- Sponsor
- Registry
-
NCT05042973
-
- Other papers using this trial's data
- The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT05042973. Randomized; quadruple masking; primary purpose prevention. Start 2021-09-02 (actual); primary completion 2025-01-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
- Condition
- Obesity
- Condition
- Heart Failure
- Intervention (Drug)
- Empagliflozin 10 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- Jacob Moller
- Collaborator
- Danish Heart Foundation
- Collaborator
- Herlev and Gentofte Hospital
- Collaborator
- University Hospital Bispebjerg and Frederiksberg
- Collaborator
- Hillerod Hospital, Denmark
- Collaborator
- Copenhagen University Hospital, Rigshospitalet
Record details
- Record id
cardio:ct-nct05042973- Content hash
7099103cce4a30e5e7bc6b6a8007345ce877a865cb5538839310492ff9ffffe8